Muzamil Mahdi ABDELHAMID’s Post

In the battle against Drug-Resistant #Malaria, scientists at UC Irvine & Yale School of Medicine introduced #MED6189 - a new drug to combat drug-sensitive and drug-resistant strains of human malaria parasites. This could be a crucial tool in global malaria eradication efforts. Quick Read: https://lnkd.in/ger-NaKu #Malaria #DrugResistance #MalariaResearch #PublicHealth #MalariaPrevention #MedicalInnovation #GlobalHealth #ScienceNews

Hope and science are a potent combination!   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives.   But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains.   It’s time to act if we want to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health

Hope and science are a powerful combination.   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of #malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives.   But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains.   It’s time to act if we want to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health

📽️ A new way of treating relapsing P. vivax #malaria is becoming available. Brazil is the first country to adopt single-dose #tafenoquine, facilitated by G6PD testing. We are pleased to be playing a part through a volume guarantee for SD BIOSENSOR INC and partnership with PATH to ensure continued availability of affordable G6PD testing devices in countries with high P. vivax malaria burden, facilitating treatment. "Now everyone knows that in order to take tafenoquine, a G6PD test is needed first." Learn more from this short film about the Tafenoquine Rollout STudy (TRuST) in Brazil, by Medicines for Malaria Venture. https://lnkd.in/ejqAqhjd

Start with the hardest to reach: A new test & treatment for relapsing P. vivax malaria in Brazil

Hope and science are a powerful combination.   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives.   But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains.   It’s time to act if we want to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health

Hope and science are a powerful combination.   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives.   But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains.   It’s time to act if we want to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health

Hope and science are a powerful combination.   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives.   But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains.   It’s time to act if we want to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health

Hope and science are a powerful combination.   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives.   But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains.   It’s time to act if we want to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health

Hope and science are a powerful combination.   Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire.   Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives.   But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains.   It’s time to act if we want to make malaria a problem of the past.   #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health